183 related articles for article (PubMed ID: 24986639)
1. First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer.
Tedaldi G; Danesi R; Zampiga V; Tebaldi M; Bedei L; Zoli W; Amadori D; Falcini F; Calistri D
BMC Cancer; 2014 Jul; 14():478. PubMed ID: 24986639
[TBL] [Abstract][Full Text] [Related]
2. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
3. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
4. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
5. CHEK2 Germ Line Mutations are Lacking among Familial and Sporadic Breast Cancer Patients in Rwanda.
Habyarimana T; Attaleb M; Mugenzi P; Mazarati JB; Bakri Y; El Mzibri M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):375-379. PubMed ID: 29479983
[TBL] [Abstract][Full Text] [Related]
6. Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin.
Baloch AH; Daud S; Raheem N; Luqman M; Ahmad A; Rehman A; Shuja J; Rasheed S; Ali A; Kakar N; Naseeb HK; Mengal MA; Awan MA; Wasim M; Baloch DM; Ahmad J
Mol Biol Rep; 2014 Feb; 41(2):1103-7. PubMed ID: 24390236
[TBL] [Abstract][Full Text] [Related]
7. Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
Fan Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
Breast Cancer Res Treat; 2018 May; 169(1):59-67. PubMed ID: 29356917
[TBL] [Abstract][Full Text] [Related]
8. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
9. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
[TBL] [Abstract][Full Text] [Related]
10. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
12. A novel CHEK2 variant identified by next generation sequencing in an Indian family with hereditary breast cancer syndrome.
Bhai P; Saxena R; Kulshrestha S; Verma IC
Cancer Genet; 2019 Jun; 235-236():13-17. PubMed ID: 31296309
[TBL] [Abstract][Full Text] [Related]
13. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.
Schutte M; Seal S; Barfoot R; Meijers-Heijboer H; Wasielewski M; Evans DG; Eccles D; Meijers C; Lohman F; Klijn J; van den Ouweland A; Futreal PA; Nathanson KL; Weber BL; Easton DF; Stratton MR; Rahman N;
Am J Hum Genet; 2003 Apr; 72(4):1023-8. PubMed ID: 12610780
[TBL] [Abstract][Full Text] [Related]
14. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.
Le Calvez-Kelm F; Lesueur F; Damiola F; Vallée M; Voegele C; Babikyan D; Durand G; Forey N; McKay-Chopin S; Robinot N; Nguyen-Dumont T; Thomas A; Byrnes GB; ; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV
Breast Cancer Res; 2011 Jan; 13(1):R6. PubMed ID: 21244692
[TBL] [Abstract][Full Text] [Related]
15. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
[TBL] [Abstract][Full Text] [Related]
16. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the c.793-1G > A splicing variant in CHEK2 gene as pathogenic: a case report.
Agiannitopoulos K; Papadopoulou E; Tsaousis GN; Pepe G; Kampouri S; Kocdor MA; Nasioulas G
BMC Med Genet; 2019 Jul; 20(1):131. PubMed ID: 31349801
[TBL] [Abstract][Full Text] [Related]
18. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
Kleiblova P; Stolarova L; Krizova K; Lhota F; Hojny J; Zemankova P; Havranek O; Vocka M; Cerna M; Lhotova K; Borecka M; Janatova M; Soukupova J; Sevcik J; Zimovjanova M; Kotlas J; Panczak A; Vesela K; Cervenkova J; Schneiderova M; Burocziova M; Burdova K; Stranecky V; Foretova L; Machackova E; Tavandzis S; Kmoch S; Macurek L; Kleibl Z
Int J Cancer; 2019 Oct; 145(7):1782-1797. PubMed ID: 31050813
[TBL] [Abstract][Full Text] [Related]
19. Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan.
Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
BMC Cancer; 2013 Jun; 13():312. PubMed ID: 23806170
[TBL] [Abstract][Full Text] [Related]
20. [Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
Nasedkina TV; Gromyko OE; Emel'ianova MA; Ignatova EO; Kazubskaia TP; Portnoĭ SM; Zasedatelev AS; Liubchenko LN
Mol Biol (Mosk); 2014; 48(2):243-50. PubMed ID: 25850293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
